Literature DB >> 12632697

Ethical issues raised by genetic testing with oligonucleotide microarrays.

Wayne W Grody1.   

Abstract

Because genes and alterations within them determine the identity, characteristics, and inheritance of every individual, the application of genetic science to humans has long been surrounded by apprehension, controversy, and real or perceived potential for abuse. Crude eugenics practices of the past now find a theoretical rebirth and transformation through the use of modern molecular genetic technologies for mutation detection, predictive and prenatal diagnosis, and, ultimately, gene replacement. The advent of oligonucleotide microarray analysis, in which hundreds or thousands of genes and mutations can be tested in parallel, offers tremendous promise for more accurate, sensitive, and efficient genetic testing. At the same time, however, this powerful technology dramatically increases the number and scope of ethical concerns accompanying each individual test request. This article considers the evolution and implications of these concerns, from the initial ordering of a microarray test by the physician to such issues as informed consent, privacy, confidentiality, clinical utility, discrimination, stigmatization, ethnic and population impact, and reimbursement.

Entities:  

Mesh:

Year:  2003        PMID: 12632697     DOI: 10.1385/MB:23:2:127

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  35 in total

1.  Bad for your health: are gene patents stopping patients getting the latest tests?

Authors:  Kurt Kleiner
Journal:  New Sci       Date:  2002-03-23       Impact factor: 0.319

2.  Pedigrees-publish? or perish the thought?

Authors:  P H Byers; J Ashkenas
Journal:  Am J Hum Genet       Date:  1998-09       Impact factor: 11.025

3.  Group identity and human diversity: keeping biology straight from culture.

Authors:  E T Juengst
Journal:  Am J Hum Genet       Date:  1998-09       Impact factor: 11.025

4.  A model agreement for genetic research in socially identifiable populations.

Authors:  M W Foster; D Bernsten; T H Carter
Journal:  Am J Hum Genet       Date:  1998-09       Impact factor: 11.025

5.  Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996.

Authors: 
Journal:  J Clin Oncol       Date:  1996-05       Impact factor: 44.544

Review 6.  Genetic testing for susceptibility to adult-onset cancer. The process and content of informed consent.

Authors:  G Geller; J R Botkin; M J Green; N Press; B B Biesecker; B Wilfond; G Grana; M B Daly; K Schneider; M J Kahn
Journal:  JAMA       Date:  1997-05-14       Impact factor: 56.272

7.  Recommended policies for uses of human tissue in research, education, and quality control. Ad Hoc Committee on Stored Tissue, College of American Pathologists.

Authors:  W Grizzle; W W Grody; W W Noll; M E Sobel; S A Stass; T Trainer; H Travers; V Weedn; K Woodruff
Journal:  Arch Pathol Lab Med       Date:  1999-04       Impact factor: 5.534

8.  BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing.

Authors:  D Shattuck-Eidens; A Oliphant; M McClure; C McBride; J Gupte; T Rubano; D Pruss; S V Tavtigian; D H Teng; N Adey; M Staebell; K Gumpper; R Lundstrom; M Hulick; M Kelly; J Holmen; B Lingenfelter; S Manley; F Fujimura; M Luce; B Ward; L Cannon-Albright; L Steele; K Offit; A Thomas
Journal:  JAMA       Date:  1997-10-15       Impact factor: 56.272

9.  The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals.

Authors:  J P Struewing; D Abeliovich; T Peretz; N Avishai; M M Kaback; F S Collins; L C Brody
Journal:  Nat Genet       Date:  1995-10       Impact factor: 38.330

10.  The Privacy Rule: HIPAA standards for the privacy of individually identifiable health information.

Authors:  Lisa W Wang
Journal:  Empl Benefits J       Date:  2002-09
View more
  5 in total

Review 1.  Keeping up with the next generation: massively parallel sequencing in clinical diagnostics.

Authors:  John R ten Bosch; Wayne W Grody
Journal:  J Mol Diagn       Date:  2008-10-02       Impact factor: 5.568

2.  Privacy and data management in the era of massively parallel next-generation sequencing.

Authors:  Frank S Ong; Wayne W Grody; Joshua L Deignan
Journal:  Expert Rev Mol Diagn       Date:  2011-06       Impact factor: 5.225

3.  Supporting Parental Decisions About Genomic Sequencing for Newborn Screening: The NC NEXUS Decision Aid.

Authors:  Megan A Lewis; Ryan S Paquin; Myra I Roche; Robert D Furberg; Christine Rini; Jonathan S Berg; Cynthia M Powell; Donald B Bailey
Journal:  Pediatrics       Date:  2016-01       Impact factor: 7.124

4.  Physicians' perspectives on the uncertainties and implications of chromosomal microarray testing of children and families.

Authors:  M Reiff; K Ross; S Mulchandani; K J Propert; R E Pyeritz; N B Spinner; B A Bernhardt
Journal:  Clin Genet       Date:  2012-09-18       Impact factor: 4.438

5.  A qualitative study of healthcare providers' perspectives on the implications of genome-wide testing in pediatric clinical practice.

Authors:  Marian Reiff; Rebecca Mueller; Surabhi Mulchandani; Nancy B Spinner; Reed E Pyeritz; Barbara A Bernhardt
Journal:  J Genet Couns       Date:  2013-09-14       Impact factor: 2.537

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.